New and pharmacologically useful 17-amino-16-hydroxy-steroids of the androstane and oestrane series are disclosed having the formula I:
and pnarmaceutically acceptable non-toxic acid addition salts thereof, wherein:
R, = H or hydrocarbyl of one to six carbon atoms (preferably lower alkyl , such as methyl);
R2 = H or hydrocarbyl of one to six carbon atoms (preferably lower alkyl, such as methyl);
R3 = a free, esterified or etherified hydroxyl group;
ring A inclusive carbon atoms 6 and 9 has one of the following configurations:
in which
R4 = a free, esterified or etherified hydroxyl group;
R5 = O or H(R7), wherein R7 is a free, esterified or etherified hydroxyl group;
R6 = H or methyl; and
the dotted lines represent an optional double bond in 4,5- or 5,6-position;
as well as the enantiomers and racemates of these steroids.
The novel compounds have antiarrhythmic properties.
本研究公开了具有式 I 的新的药理作用的雄烷和雌烷系列 17-
氨基-16-羟基类
固醇:
及其药学上可接受的无毒酸加成盐,其中
R,=H 或一至六个碳原子的烃基(最好是低级烷基,如甲基);
R2 = H 或一至六个碳原子的烃基(最好是低级烷基,如甲基);
R3 = 自由的、酯化的或醚化的羟基;
包含碳原子 6 和 9 的环 A 具有下列构型之一:
其中
R4 = 自由、酯化或醚化羟基;
R5 = O 或 H(R7),其中 R7 是游离的、酯化的或醚化的羟基;
R6 = H 或甲基;以及
虚线代表 4,5- 位或 5,6- 位的任选双键;
以及这些类
固醇的对映体和外消旋体。
这些新型化合物具有抗心律失常的特性。